Blood Cancer Talks cover image

Episode 15. Management of Newly Diagnosed DLBCL (Including Bonus ASH22 Updates)

Blood Cancer Talks

00:00

Bi-Specific Antibodies for Lymphoma

There is a subset of patients who benefit significantly and are probably being cured by these bi-specific antibodies. Most likely it's going to be about 20 to 30% patients who achieve long-term remission which will end into a cure. For example, if you look at the curves for long-cast oxy-map, also there are about 20% patients who haven't relapsed after long follow-up. Same thing for Linnilidomide and Tafacetimab.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app